Cadrenal Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 5.17 million. Basic loss per share from continuing operations was USD 0.48.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4301 USD | -3.00% | -11.39% | -41.87% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-41.87% | 7.1M | |
+32.36% | 709B | |
+30.77% | 595B | |
-1.60% | 367B | |
+20.07% | 334B | |
+6.04% | 289B | |
+14.77% | 239B | |
+9.13% | 211B | |
-3.97% | 203B | |
+9.27% | 171B |
- Stock Market
- Equities
- CVKD Stock
- News Cadrenal Therapeutics, Inc.
- Cadrenal Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023